{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:28:15Z","timestamp":1772119695690,"version":"3.50.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10928-024-09912-z","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T12:02:01Z","timestamp":1711800121000},"page":"367-384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions"],"prefix":"10.1007","volume":"51","author":[{"given":"Tongtong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sufeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tangping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,30]]},"reference":[{"issue":"1","key":"9912_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL et al (2022) Cancer statistics, 2022. CA: Cancer J Clin 72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708","journal-title":"CA: Cancer J Clin"},{"issue":"3","key":"9912_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA: Cancer J Clin"},{"issue":"1","key":"9912_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12282-016-0666-7","volume":"24","author":"K Nakatsukasa","year":"2017","unstructured":"Nakatsukasa K et al (2017) Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer. Breast Cancer 24(1):63\u201368. https:\/\/doi.org\/10.1007\/s12282-016-0666-7","journal-title":"Breast Cancer"},{"issue":"1","key":"9912_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/ppo.0000000000000498","volume":"27","author":"A Marra","year":"2021","unstructured":"Marra A, Curigliano G (2021) Adjuvant and neoadjuvant treatment of triple-negative breast cancer with chemotherapy. Cancer J 27(1):41\u201349. https:\/\/doi.org\/10.1097\/ppo.0000000000000498","journal-title":"Cancer J"},{"issue":"1","key":"9912_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejon.2008.10.003","volume":"13","author":"J Baker","year":"2009","unstructured":"Baker J et al (2009) Docetaxel-related side effects and their management. Eur J Oncol Nurs 13(1):49\u201359. https:\/\/doi.org\/10.1016\/j.ejon.2008.10.003","journal-title":"Eur J Oncol Nurs"},{"issue":"4","key":"9912_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/030089169608200414","volume":"82","author":"D Nicolella","year":"1996","unstructured":"Nicolella D et al (1996) Weekly low dose epirubicin in elderly cancer patients. Tumori 82(4):369\u2013371. https:\/\/doi.org\/10.1177\/030089169608200414","journal-title":"Tumori"},{"issue":"4","key":"9912_CR7","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1177\/030089160609200421","volume":"92","author":"S Gori","year":"2006","unstructured":"Gori S et al (2006) Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment. Tumori 92(4):364\u2013365. https:\/\/doi.org\/10.1177\/030089160609200421","journal-title":"Tumori"},{"issue":"Suppl 1","key":"9912_CR8","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.critrevonc.2013.05.012","volume":"88","author":"GJ Morgan","year":"2013","unstructured":"Morgan GJ, Davies FE (2013) Role of thalidomide in the treatment of patients with multiple myeloma. Crit Rev Oncol Hematol 88(Suppl 1):S14-22. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.05.012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"9912_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.18926\/amo\/54607","volume":"70","author":"T Tamura","year":"2016","unstructured":"Tamura T et al (2016) A phase i trial of 100 mg\/m2 docetaxel in patients with advanced or recurrent breast cancer. Acta Med Okayama 70(5):425\u2013427. https:\/\/doi.org\/10.18926\/amo\/54607","journal-title":"Acta Med Okayama"},{"issue":"2","key":"9912_CR10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/bcp.14678","volume":"87","author":"M Muth","year":"2021","unstructured":"Muth M et al (2021) Role of TDM-based dose adjustments for taxane anticancer drugs. Br J Clin Pharmacol 87(2):306\u2013316. https:\/\/doi.org\/10.1111\/bcp.14678","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"9912_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2165\/00003088-200645030-00002","volume":"45","author":"SD Baker","year":"2006","unstructured":"Baker SD, Sparreboom A, Verweij J (2006) Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet 45(3):235\u2013252. https:\/\/doi.org\/10.2165\/00003088-200645030-00002","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"9912_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/00003088-199936020-00002","volume":"36","author":"SJ Clarke","year":"1999","unstructured":"Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36(2):99\u2013114. https:\/\/doi.org\/10.2165\/00003088-199936020-00002","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"9912_CR13","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/j.1349-7006.1999.tb00723.x","volume":"90","author":"K Shirakawa","year":"1999","unstructured":"Shirakawa K et al (1999) Interaction of docetaxel (\u201cTaxotere\u201d) with human P-glycoprotein. Jpn J Cancer Res 90(12):1380\u20131386. https:\/\/doi.org\/10.1111\/j.1349-7006.1999.tb00723.x","journal-title":"Jpn J Cancer Res"},{"issue":"1","key":"9912_CR14","doi-asserted-by":"publisher","first-page":"13570","DOI":"10.1038\/s41598-022-17447-x","volume":"12","author":"SA Dyshlovoy","year":"2022","unstructured":"Dyshlovoy SA et al (2022) New diterpenes from the marine sponge Spongionella sp. overcome drug resistance in prostate cancer by inhibition of P-glycoprotein. Sci Rep 12(1):13570. https:\/\/doi.org\/10.1038\/s41598-022-17447-x","journal-title":"Sci Rep"},{"issue":"1","key":"9912_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.toxlet.2014.11.005","volume":"232","author":"G Vredenburg","year":"2015","unstructured":"Vredenburg G et al (2015) Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants. Toxicol Lett 232(1):182\u2013192. https:\/\/doi.org\/10.1016\/j.toxlet.2014.11.005","journal-title":"Toxicol Lett"},{"issue":"11","key":"9912_CR16","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","volume":"44","author":"ME de Jonge","year":"2005","unstructured":"de Jonge ME et al (2005) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 44(11):1135\u20131164. https:\/\/doi.org\/10.2165\/00003088-200544110-00003","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"9912_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s002800000220","volume":"47","author":"SM Yule","year":"2001","unstructured":"Yule SM et al (2001) Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion. Cancer Chemother Pharmacol 47(3):222\u2013228. https:\/\/doi.org\/10.1007\/s002800000220","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"9912_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1023\/a:1023234429596","volume":"20","author":"H Martin","year":"2003","unstructured":"Martin H et al (2003) Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. Pharm Res 20(4):557\u2013568. https:\/\/doi.org\/10.1023\/a:1023234429596","journal-title":"Pharm Res"},{"issue":"3","key":"9912_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1200\/jco.1986.4.3.425","volume":"4","author":"RJ Cersosimo","year":"1986","unstructured":"Cersosimo RJ, Hong WK (1986) Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 4(3):425\u2013439. https:\/\/doi.org\/10.1200\/jco.1986.4.3.425","journal-title":"J Clin Oncol"},{"issue":"8","key":"9912_CR20","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.3109\/10717544.2015.1136713","volume":"23","author":"M Tariq","year":"2016","unstructured":"Tariq M et al (2016) Improved oral efficacy of epirubicin through polymeric nanoparticles: pharmacodynamic and toxicological investigations. Drug Deliv 23(8):2990\u20132997. https:\/\/doi.org\/10.3109\/10717544.2015.1136713","journal-title":"Drug Deliv"},{"issue":"1","key":"9912_CR21","doi-asserted-by":"publisher","first-page":"100876","DOI":"10.1016\/j.tranon.2020.100876","volume":"14","author":"K Liu","year":"2021","unstructured":"Liu K et al (2021) Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-\u03baB pathway. Transl Oncol 14(1):100876. https:\/\/doi.org\/10.1016\/j.tranon.2020.100876","journal-title":"Transl Oncol"},{"issue":"7","key":"9912_CR22","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1124\/dmd.30.7.814","volume":"30","author":"C Lindley","year":"2002","unstructured":"Lindley C et al (2002) The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos 30(7):814\u2013822. https:\/\/doi.org\/10.1124\/dmd.30.7.814","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"9912_CR23","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3109\/02841868909092323","volume":"28","author":"S Eksborg","year":"1989","unstructured":"Eksborg S (1989) Pharmacokinetics of anthracyclines. Acta Oncol 28(6):873\u2013876. https:\/\/doi.org\/10.3109\/02841868909092323","journal-title":"Acta Oncol"},{"issue":"1","key":"9912_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12885-020-06855-9","volume":"20","author":"M Ismail","year":"2020","unstructured":"Ismail M et al (2020) Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy. BMC Cancer 20(1):335. https:\/\/doi.org\/10.1186\/s12885-020-06855-9","journal-title":"BMC Cancer"},{"issue":"2","key":"9912_CR25","doi-asserted-by":"publisher","first-page":"e35324","DOI":"10.7759\/cureus.35324","volume":"15","author":"J Rodrigues","year":"2023","unstructured":"Rodrigues J et al (2023) Mitigating the risk of drug interactions in cancer patients taking oral anticancer agents: the role of a multidisciplinary team-based medication reconciliation. Cureus 15(2):e35324. https:\/\/doi.org\/10.7759\/cureus.35324","journal-title":"Cureus"},{"issue":"4","key":"9912_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","volume":"77","author":"A Mueller-Schoell","year":"2021","unstructured":"Mueller-Schoell A et al (2021) Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol 77(4):441\u2013464. https:\/\/doi.org\/10.1007\/s00228-020-03014-8","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"9912_CR27","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/17425255.2021.1943357","volume":"17","author":"A Fahmy","year":"2021","unstructured":"Fahmy A et al (2021) Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature. Expert Opin Drug Metab Toxicol 17(7):803\u2013821. https:\/\/doi.org\/10.1080\/17425255.2021.1943357","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"9912_CR28","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s11095-022-03274-2","volume":"39","author":"W Lin","year":"2022","unstructured":"Lin W et al (2022) Applications, challenges, and outlook for PBPK modeling and simulation: a regulatory. Ind Acad Perspect Pharm Res 39(8):1701\u20131731. https:\/\/doi.org\/10.1007\/s11095-022-03274-2","journal-title":"Ind Acad Perspect Pharm Res"},{"issue":"10","key":"9912_CR29","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/psp4.12134","volume":"5","author":"L Kuepfer","year":"2016","unstructured":"Kuepfer L et al (2016) Applied concepts in PBPK modeling: how to build a PBPK\/PD model. CPT Pharmacometrics Syst Pharmacol 5(10):516\u2013531. https:\/\/doi.org\/10.1002\/psp4.12134","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"9912_CR30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejps.2011.04.008","volume":"43","author":"K Rowland Yeo","year":"2011","unstructured":"Rowland Yeo K et al (2011) Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur J Pharm Sci 43(3):160\u2013173. https:\/\/doi.org\/10.1016\/j.ejps.2011.04.008","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"9912_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/1389200221666200620210522","volume":"21","author":"S Sudsakorn","year":"2020","unstructured":"Sudsakorn S et al (2020) 2020 FDA drug-drug interaction guidance: a comparison analysis and action plan by pharmaceutical industrial scientists. Curr Drug Metab 21(6):403\u2013426. https:\/\/doi.org\/10.2174\/1389200221666200620210522","journal-title":"Curr Drug Metab"},{"key":"9912_CR32","doi-asserted-by":"publisher","first-page":"105355","DOI":"10.1016\/j.ejps.2020.105355","volume":"150","author":"MS Mendes","year":"2020","unstructured":"Mendes MS et al (2020) A physiologically based pharmacokinetic\u2014pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients. Eur J Pharm Sci 150:105355. https:\/\/doi.org\/10.1016\/j.ejps.2020.105355","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"9912_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/bdd.1830","volume":"34","author":"S Cheeti","year":"2013","unstructured":"Cheeti S et al (2013) A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharm Drug Dispos 34(3):141\u2013154. https:\/\/doi.org\/10.1002\/bdd.1830","journal-title":"Biopharm Drug Dispos"},{"issue":"24","key":"9912_CR34","doi-asserted-by":"publisher","first-page":"8341","DOI":"10.1158\/1078-0432.Ccr-04-1371","volume":"10","author":"SD Baker","year":"2004","unstructured":"Baker SD et al (2004) Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 10(24):8341\u20138350. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-1371","journal-title":"Clin Cancer Res"},{"issue":"5","key":"9912_CR35","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1200\/jco.2004.03.050","volume":"22","author":"B Peng","year":"2004","unstructured":"Peng B et al (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22(5):935\u2013942. https:\/\/doi.org\/10.1200\/jco.2004.03.050","journal-title":"J Clin Oncol"},{"issue":"4","key":"9912_CR36","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/sam.11583","volume":"15","author":"VR Joseph","year":"2022","unstructured":"Joseph VR (2022) Optimal ratio for data splitting. Statist Analy Data Mining 15(4):531\u2013538. https:\/\/doi.org\/10.1002\/sam.11583","journal-title":"Statist Analy Data Mining"},{"issue":"4","key":"9912_CR37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/08982104.2020.1835955","volume":"31","author":"A Singh","year":"2021","unstructured":"Singh A et al (2021) Novel vitamin E TPGS based docetaxel nanovesicle formulation for its safe and effective parenteral delivery: toxicological, pharmacokinetic and pharmacodynamic evaluation. J Liposome Res 31(4):365\u2013380. https:\/\/doi.org\/10.1080\/08982104.2020.1835955","journal-title":"J Liposome Res"},{"key":"9912_CR38","first-page":"305","volume":"17","author":"R Bruno","year":"1993","unstructured":"Bruno R, Sanderink GJ (1993) Pharmacokinetics and metabolism of taxotere (docetaxel). Cancer Surv 17:305\u2013313","journal-title":"Cancer Surv"},{"issue":"6","key":"9912_CR39","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/jps.20323","volume":"94","author":"T Rodgers","year":"2005","unstructured":"Rodgers T, Leahy D, Rowland M (2005) Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. J Pharm Sci 94(6):1237\u20131248. https:\/\/doi.org\/10.1002\/jps.20323","journal-title":"J Pharm Sci"},{"issue":"6","key":"9912_CR40","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/jps.20502","volume":"95","author":"T Rodgers","year":"2006","unstructured":"Rodgers T, Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95(6):1238\u20131257. https:\/\/doi.org\/10.1002\/jps.20502","journal-title":"J Pharm Sci"},{"issue":"3","key":"9912_CR41","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3390\/pharmaceutics11030135","volume":"11","author":"SY Han","year":"2019","unstructured":"Han SY et al (2019) LC478, a novel di-substituted adamantyl derivative, enhances the oral bioavailability of docetaxel in rats. Pharmaceutics 11(3):135. https:\/\/doi.org\/10.3390\/pharmaceutics11030135","journal-title":"Pharmaceutics"},{"issue":"4","key":"9912_CR42","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.3390\/pharmaceutics15041222","volume":"15","author":"R Ansaar","year":"2023","unstructured":"Ansaar R, Meech R, Rowland A (2023) A physiologically based pharmacokinetic model to predict determinants of variability in epirubicin exposure and tissue distribution. Pharmaceutics 15(4):1222. https:\/\/doi.org\/10.3390\/pharmaceutics15041222","journal-title":"Pharmaceutics"},{"issue":"1","key":"9912_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00001813-199801000-00001","volume":"9","author":"A Sparreboom","year":"1998","unstructured":"Sparreboom A et al (1998) Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 9(1):1\u201317. https:\/\/doi.org\/10.1097\/00001813-199801000-00001","journal-title":"Anticancer Drugs"},{"issue":"7","key":"9912_CR44","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1177\/1060028019896894","volume":"54","author":"T Cai","year":"2020","unstructured":"Cai T et al (2020) The influence of different triazole antifungal agents on the pharmacokinetics of cyclophosphamide. Ann Pharmacother 54(7):676\u2013683. https:\/\/doi.org\/10.1177\/1060028019896894","journal-title":"Ann Pharmacother"},{"issue":"6","key":"9912_CR45","doi-asserted-by":"publisher","first-page":"428","DOI":"10.2165\/00003088-199426060-00002","volume":"26","author":"J Robert","year":"1994","unstructured":"Robert J (1994) Clinical pharmacokinetics of epirubicin. Clin Pharmacokinet 26(6):428\u2013438. https:\/\/doi.org\/10.2165\/00003088-199426060-00002","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"9912_CR46","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1476-5381.1971.tb07199.x","volume":"43","author":"JL Cohen","year":"1971","unstructured":"Cohen JL, Jao JY, Jusko WJ (1971) Pharmacokinetics of cyclophosphamide in man. Br J Pharmacol 43(3):677\u2013680. https:\/\/doi.org\/10.1111\/j.1476-5381.1971.tb07199.x","journal-title":"Br J Pharmacol"},{"issue":"5","key":"9912_CR47","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/00008571-199810000-00004","volume":"8","author":"M Shou","year":"1998","unstructured":"Shou M et al (1998) Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8(5):391\u2013401. https:\/\/doi.org\/10.1097\/00008571-199810000-00004","journal-title":"Pharmacogenetics"},{"issue":"8","key":"9912_CR48","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/s0006-2952(99)00410-4","volume":"59","author":"Z Huang","year":"2000","unstructured":"Huang Z, Roy P, Waxman DJ (2000) Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 59(8):961\u2013972. https:\/\/doi.org\/10.1016\/s0006-2952(99)00410-4","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"9912_CR49","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/jat.1283","volume":"28","author":"T Iwakiri","year":"2008","unstructured":"Iwakiri T et al (2008) Inhibition of carrier-mediated uptake of epirubicin reduces cytotoxicity in primary culture of rat hepatocytes. J Appl Toxicol 28(3):329\u2013336. https:\/\/doi.org\/10.1002\/jat.1283","journal-title":"J Appl Toxicol"},{"issue":"12","key":"9912_CR50","doi-asserted-by":"publisher","first-page":"517","DOI":"10.5414\/cpp39517","volume":"39","author":"M Baumh\u00e4kel","year":"2001","unstructured":"Baumh\u00e4kel M et al (2001) Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther 39(12):517\u2013528. https:\/\/doi.org\/10.5414\/cpp39517","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"9912_CR51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00420-007-0211-2","volume":"81","author":"M Hedmer","year":"2008","unstructured":"Hedmer M et al (2008) Validation of urinary excretion of cyclophosphamide as a biomarker of exposure by studying its renal clearance at high and low plasma concentrations in cancer patients. Int Arch Occup Environ Health 81(3):285\u2013293. https:\/\/doi.org\/10.1007\/s00420-007-0211-2","journal-title":"Int Arch Occup Environ Health"},{"issue":"12","key":"9912_CR52","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s12272-014-0475-5","volume":"37","author":"DH Shin","year":"2014","unstructured":"Shin DH et al (2014) Hepatic uptake of epirubicin by isolated rat hepatocytes and its biliary excretion after intravenous infusion in rats. Arch Pharm Res 37(12):1599\u20131606. https:\/\/doi.org\/10.1007\/s12272-014-0475-5","journal-title":"Arch Pharm Res"},{"issue":"5","key":"9912_CR53","first-page":"686","volume":"29","author":"F Innocenti","year":"2001","unstructured":"Innocenti F et al (2001) Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 29(5):686\u2013692","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"9912_CR54","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/psp4.12166","volume":"6","author":"P Zhao","year":"2017","unstructured":"Zhao P (2017) Report from the EMA workshop on qualification and reporting of physiologically based pharmacokinetic (PBPK) modeling and simulation. CPT Pharmacometrics Syst Pharmacol 6(2):71\u201372. https:\/\/doi.org\/10.1002\/psp4.12166","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"9","key":"9912_CR55","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1124\/dmd.114.058099","volume":"42","author":"K Abduljalil","year":"2014","unstructured":"Abduljalil K et al (2014) Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations. Drug Metab Dispos 42(9):1478\u20131484. https:\/\/doi.org\/10.1124\/dmd.114.058099","journal-title":"Drug Metab Dispos"},{"key":"9912_CR56","doi-asserted-by":"publisher","first-page":"137","DOI":"10.18773\/austprescr.2014.050","volume":"37","author":"A Finch","year":"2014","unstructured":"Finch A, Pillans P (2014) P-glycoprotein and its role in drug-drug interactions. Aust Prescriber 37:137\u2013139. https:\/\/doi.org\/10.18773\/austprescr.2014.050","journal-title":"Aust Prescriber"},{"key":"9912_CR57","doi-asserted-by":"publisher","first-page":"780937","DOI":"10.3389\/fphar.2021.780937","volume":"12","author":"H Liu","year":"2021","unstructured":"Liu H et al (2021) Application of physiologically based pharmacokinetic modeling to evaluate the drug-drug and drug-disease interactions of apatinib. Front Pharmacol 12:780937. https:\/\/doi.org\/10.3389\/fphar.2021.780937","journal-title":"Front Pharmacol"},{"issue":"3","key":"9912_CR58","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4140\/TCP.n.2013.176","volume":"28","author":"MW Davis","year":"2013","unstructured":"Davis MW, Wason S, Digiacinto JL (2013) Colchicine-antimicrobial drug interactions: what pharmacists need to know in treating gout. Consult Pharm 28(3):176\u2013183. https:\/\/doi.org\/10.4140\/TCP.n.2013.176","journal-title":"Consult Pharm"},{"issue":"3","key":"9912_CR59","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/0091270008325931","volume":"49","author":"C Oo","year":"2009","unstructured":"Oo C, Chen YC (2009) The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study. J Clin Pharmacol 49(3):368\u2013369. https:\/\/doi.org\/10.1177\/0091270008325931","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"9912_CR60","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/clpt.2014.41","volume":"95","author":"AB Ke","year":"2014","unstructured":"Ke AB et al (2014) Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. Clin Pharmacol Ther 95(5):473\u2013476. https:\/\/doi.org\/10.1038\/clpt.2014.41","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9912_CR61","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ijpharm.2018.07.011","volume":"548","author":"P Khadka","year":"2018","unstructured":"Khadka P et al (2018) Considerations in preparing for clinical studies of inhaled rifampicin to enhance tuberculosis treatment. Int J Pharm 548(1):244\u2013254. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.07.011","journal-title":"Int J Pharm"},{"issue":"5","key":"9912_CR62","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/cas.12647","volume":"106","author":"H Kenmotsu","year":"2015","unstructured":"Kenmotsu H, Tanigawara Y (2015) Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the Western dose. Cancer Sci 106(5):497\u2013504. https:\/\/doi.org\/10.1111\/cas.12647","journal-title":"Cancer Sci"},{"issue":"10","key":"9912_CR63","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/sj.bjc.6600626","volume":"87","author":"PA Vasey","year":"2002","unstructured":"Vasey PA et al (2002) Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer. Br J Cancer 87(10):1072\u20131078. https:\/\/doi.org\/10.1038\/sj.bjc.6600626","journal-title":"Br J Cancer"},{"issue":"11","key":"9912_CR64","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/annonc\/mdf305","volume":"13","author":"D Rischin","year":"2002","unstructured":"Rischin D et al (2002) Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics. Ann Oncol 13(11):1810\u20131818. https:\/\/doi.org\/10.1093\/annonc\/mdf305","journal-title":"Ann Oncol"},{"issue":"5","key":"9912_CR65","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.clpt.2004.01.001","volume":"75","author":"FK Engels","year":"2004","unstructured":"Engels FK et al (2004) Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 75(5):448\u2013454. https:\/\/doi.org\/10.1016\/j.clpt.2004.01.001","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9912_CR66","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.xphs.2018.10.033","volume":"108","author":"M Grimstein","year":"2019","unstructured":"Grimstein M et al (2019) Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration\u2019s Office of clinical pharmacology. J Pharm Sci 108(1):21\u201325. https:\/\/doi.org\/10.1016\/j.xphs.2018.10.033","journal-title":"J Pharm Sci"},{"issue":"1","key":"9912_CR67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40262-014-0188-4","volume":"54","author":"C Wagner","year":"2015","unstructured":"Wagner C et al (2015) Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration. Clin Pharmacokinet 54(1):117\u2013127. https:\/\/doi.org\/10.1007\/s40262-014-0188-4","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"9912_CR68","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40262-015-0330-y","volume":"55","author":"C Wagner","year":"2016","unstructured":"Wagner C et al (2016) Predicting the effect of CYP3A inducers on the pharmacokinetics of substrate drugs using physiologically based pharmacokinetic (PBPK) modeling: an analysis of PBPK submissions to the US FDA. Clin Pharmacokinet 55(4):475\u2013483. https:\/\/doi.org\/10.1007\/s40262-015-0330-y","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"9912_CR69","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ijantimicag.2016.08.021","volume":"48","author":"M Alevizakos","year":"2016","unstructured":"Alevizakos M et al (2016) Colonisation with extended-spectrum \u03b2-lactamase-producing enterobacteriaceae and risk for infection among patients with solid or haematological malignancy: a systematic review and meta-analysis. Int J Antimicrob Agents 48(6):647\u2013654. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.08.021","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"9912_CR70","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/21505594.2016.1141161","volume":"7","author":"C Gudiol","year":"2016","unstructured":"Gudiol C, Aguado JM, Carratal\u00e0 J (2016) Bloodstream infections in patients with solid tumors. Virulence 7(3):298\u2013308. https:\/\/doi.org\/10.1080\/21505594.2016.1141161","journal-title":"Virulence"},{"key":"9912_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejps.2014.02.002","volume":"56","author":"G Baneyx","year":"2014","unstructured":"Baneyx G et al (2014) Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration. Eur J Pharm Sci 56:1\u201315. https:\/\/doi.org\/10.1016\/j.ejps.2014.02.002","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"9912_CR72","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1002\/ctm2.354","volume":"11","author":"Y Ma","year":"2021","unstructured":"Ma Y et al (2021) Therapeutic drug monitoring of docetaxel by pharmacokinetics and pharmacogenetics: a randomized clinical trial of AUC-guided dosing in nonsmall cell lung cancer. Clin Transl Med 11(4):e354. https:\/\/doi.org\/10.1002\/ctm2.354","journal-title":"Clin Transl Med"},{"key":"9912_CR73","doi-asserted-by":"publisher","unstructured":"(2007) American Society of Clinical Oncology 2007 clinical practice guideline recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Oncol Pract 3(6), 326\u2013329. https:\/\/doi.org\/10.1200\/jop.0768502","DOI":"10.1200\/jop.0768502"},{"issue":"3","key":"9912_CR74","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bcp.12702","volume":"80","author":"HT Thai","year":"2015","unstructured":"Thai HT et al (2015) Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel. Br J Clin Pharmacol 80(3):534\u2013547. https:\/\/doi.org\/10.1111\/bcp.12702","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-024-09912-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-024-09912-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-024-09912-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T16:27:19Z","timestamp":1721233639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-024-09912-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,30]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["9912"],"URL":"https:\/\/doi.org\/10.1007\/s10928-024-09912-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3802635\/v1","asserted-by":"object"}]},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,30]]},"assertion":[{"value":"25 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}